AVITA Medical's PermeaDerm-I Study Shows 70% Cost Advantage Over Allograft with Comparable Clinical Outcomes
核心洞察
AVITA Medical's PermeaDerm (搜索)-I randomized controlled trial met its primary endpoint, demonstrating a 70% economic advantage over cadaveric allograft based on product cost per percent total body surface area treated (p<0.001).
Mean treatment cost was $148.70 per 1% TBSA with PermeaDerm (搜索) versus $497.10 for allograft, representing savings of approximately $348 per %TBSA.
PermeaDerm (搜索) reduced preparation time by 95.7% while delivering comparable clinical outcomes, including graft take, wound healing, and safety, with no adverse events attributed to the product.
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) announced positive results from its multicenter, randomized controlled PermeaDerm (搜索)-I clinical study, demonstrating that PermeaDerm, a biosynthetic wound matrix, delivered clinically comparable outcomes to cadaveric allograft while reducing product cost by 70%. The study met its primary endpoint, showing statistically significant superiority (p<0.001) for mean cost per percent total body surface area (%TBSA) treated.
Mean treatment cost was $148.70 for every 1% TBSA treated with PermeaDerm (搜索) compared with $497.10 for allograft, representing a savings of approximately $348 per %TBSA. As an off-the-shelf product, PermeaDerm reduced preparation time by 95.7% compared with allograft by eliminating tissue tracking, thawing, and meshing, while maintaining comparable application time in the operating room.
Clinical Outcomes and Study Design
Clinical outcomes were comparable between treatment groups. Approximately 94% of PermeaDerm (搜索) patients achieved at least 95% graft take one week following autografting, comparable to allograft, and all patients in both groups achieved 95% or greater wound healing by eight weeks. No adverse events were attributed to PermeaDerm during the study.
The randomized controlled study enrolled 40 patients across 11 U.S. burn centers with wounds involving up to 30% TBSA eligible. Following excision, patients were randomized to receive either PermeaDerm (搜索) or cadaveric allograft during the temporization period before definitive split-thickness skin grafting. Patients were followed for eight weeks following definitive closure.
The primary endpoint evaluated treatment cost per percent total body surface area treated. Secondary endpoints included preparation time, application time, graft take, wound healing, inflammatory profile, adverse events, and surgeon and patient satisfaction. At final follow-up, all responding investigators and patients reported satisfaction, with responses rated as satisfied or very satisfied.
Investigator and Leadership Perspectives
"Temporary wound coverage is a critical step between excision and definitive closure when a wound bed is not yet ready for autograft placement," said Anju Saraswat, MD, Associate Burn Director and Assistant Professor of Surgery at Atrium Health Wake Forest Baptist Burn Center and study investigator. "These results demonstrate that PermeaDerm (搜索) provided clinical performance comparable to allograft with the added benefit of product transparency enabling direct visualization of the wound bed. By eliminating tissue bank logistics and preparation time, PermeaDerm offers a more efficient approach to wound temporization without any compromise to healing outcomes and reducing cost."
"The PermeaDerm (搜索)-I study establishes compelling clinical and economic evidence supporting PermeaDerm as a modern alternative to allograft," said Cary Vance, President and Chief Executive Officer of AVITA Medical. "By combining comparable clinical performance with meaningful economic value and a simpler workflow, we believe PermeaDerm addresses an important need for hospitals while strengthening AVITA's differentiated acute wound care portfolio."
About PermeaDerm
PermeaDerm (搜索) is a biosynthetic wound matrix designed to provide temporary wound coverage during the period between surgical excision and definitive closure. The transparent bilayer matrix protects and stabilizes the wound while allowing clinicians to visualize the wound bed without removing the product. PermeaDerm can be used to temporarily stabilize and protect the wound before subsequent reconstruction, and is part of AVITA Medical's broader acute wound care portfolio alongside Cohealyx (搜索) and RECELL (搜索).
PermeaDerm (搜索)-I is a post-market multicenter, randomized controlled clinical trial evaluating PermeaDerm compared with cadaveric allograft in patients with acute wounds requiring temporary coverage prior to definitive skin grafting. The trial is registered at ClinicalTrials.gov (NCT06750809).
AVITA Medical will host a Key Opinion Leader webinar featuring Dr. Anju Saraswat and Dr. Christina Sharon, Burn and Acute Care Surgeon, Burn Center Director at Baton Rouge General, to review the PermeaDerm (搜索)-I clinical data on Tuesday, August 18, 2026, at 4:30 p.m. Eastern Time.